| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 4.4K | 15.6% |
| Total Income | 4.5K | 15.5% |
| Expenditure | 4.0K | 7.2% |
| PBT | 486.80 | 212.3% |
| Net Profit | 459.40 | 466.5% |
| OPM | 24.87% | 38.68pp |
| NPM | 10.31% | 8.21pp |
| EPS | 2.88 | 1271.4% |
Biocon Ltd Achieves 15% YoY Growth in Q4 FY25 Operating Revenue
15 May 2025 · 15 May 2025, 10:52 pm
Summary
Biocon Ltd has reported a 15% year-over-year growth in Q4 FY25 operating revenue, reaching INR 4,417 crores. This growth was driven by a 46% year-on-year growth for Generics, 9% for Biosimilars, and 11% for Research Services. The company's Core EBITDA for the quarter stood at INR 1,363 crores, with a healthy core operating margin of 31%.
Key Highlights
- 1
15% YoY growth in Q4 FY25 operating revenue
- 2
46% year-on-year growth for Generics
- 3
9% growth for Biosimilars
- 4
11% growth for Research Services
- 5
INR 1,363 crores Core EBITDA for the quarter
- 6
31% core operating margin
- 7
Launch of Lenalidomide, Liraglutide in the U.K., and Dasatinib in the U.S.
- 8
Approvals for Liraglutide in the EU and Everolimus (Zortress®) tablets in the U.S.
- 9
Commencement of supplies of Tacrolimus to China
Management Comments
Dr. Kiran Mazumdar Shaw
The group achieved a robust 15% year-over-year and 16% sequential growth in operating revenue on a like-for-like basis. This quarter's performance was bolstered by strong growth in Generics, steady progress in Biosimilars and ongoing traction in Research Services.
Informational and educational content only. Not investment advice.